PBAC Approves XIFAXAN® (Rifaxamin a) 550 mg Cost Effectiveness in Australia

London (ots/PRNewswire) -

Norgine today announced that the Australian assessment body the
Pharmaceutical Benefits Advisory Committee (PBAC) has recommended the
use of XIFAXAN 550 mg in the prevention of the recurrence of hepatic
encephalopathy (HE) where other treatments have failed or are
contraindicated; a potentially life-threatening neuropsychiatric
condition associated with liver disease.

XIFAXAN 550 mg is the only treatment that has demonstrated a
reduction in the recurrence of episodes of overt HE and
hospitalisation due to HE compared with placebo in a 6-month
randomised, double blind, placebo-controlled study[i] in which 91%
patients were taking concomitant lactulose in both arms, in patients
who were in remission from HE, resulting from chronic liver disease.

The PBAC announced its final decision as follows:

The PBAC recommended listing of rifaximin on the basis of high
clinical need, improved clinical benefit over the existing treatments
and acceptable cost effectiveness.

On the basis of the information available to it at the April 2013
meeting, the PBAC considered that there was no longer a requirement
for a managed entry scheme approach.

This outcome represents the first acceptance for use made by a health
technology assessment (HTA) process for XIFAXAN 550 mg in their
healthcare system based on cost effectiveness review. Norgine and
Alfa Wassermann are working closely with other HTA bodies across
Europe including the National Institute for Health and Care
Excellence (NICE) and The Scottish Medicines Consortium (SMC) to
ensure patients have appropriate access to this important medicine.
The review processes are currently underway and Norgine expects these
bodies to make their decision in the second half of 2013.

'It's critical that we deliver medicines that treat serious
conditions and improve quality-of-life as well as alleviate the cost
burden on healthcare systems caused by hospital admissions," said
Peter Martin, Norgine Chief Operating Officer.

"XIFAXAN 550 mg provides healthcare professionals with a
world-leading treatment option for patients with hepatic
encephalopathy, which is a recognised growing problem that may lead
to premature death," added Peter Martin.

Norgine currently holds marketing rights for XIFAXAN 550* in:
Australia, Belgium, Denmark, Egypt, Finland, France, Germany,
Ireland, Luxembourg, the Netherlands, New Zealand, Norway,
Switzerland, Sweden and the UK.

In Europe, XIFAXAN(R) 550 mg /TARGAXAN(R) 550 mg is already available
in Denmark, Germany and in the UK for healthcare professionals to
prescribe in accordance with local guidance.

* Product under licence from Alfa Wassermann S.p.A. XIFAXAN(R) and
TARGAXAN(R) are registered trademarks of the Alfa Wassermann group of
companies, licensed to the Norgine group of companies.

Notes to editors

About the PBAC

The PBAC is the independent, expert advisory body comprising doctors,
other health professionals and a consumer representative, which makes
recommendations to the Australian Government about Pharmaceutical
Benefits Scheme (PBS) listings. The Government cannot list a medicine
on the PBS unless the PBAC makes a recommendation in favour of its
listing.

About Hepatic Encephalopathy

Hepatic encephalopathy is the term used to describe a complex and
variable neuropsychiatric condition of patients with acute or chronic
liver disease, more commonly associated with cirrhosis. Patients with
hepatic encephalopathy may experience symptoms ranging from subtle,
clinically indiscernible neurological abnormalities, to severe
neurological impairment.

XIFAXAN 550 mg Pivotal Clinical Trial

The pivotal clinical trial by Bass et al (2010) , in which patients
in remission from recurrent episodes of hepatic encephalopathy due to
cirrhosis who were treated with XIFAXAN 550mg twice-daily (bd) with
or without lactulose*, were compared with patients given placebo (bd)
with or without lactulose* over 6 months, demonstrated:

- A 58% relative reduction in the risk of breakthrough episodes of 
overt
  hepatic encephalopathy over 6 months (Hazard ratio 0.42; p<0.001). 
Thus the numbers
  needed to treat (NNT) = 4
- A 50% relative reduction in the risk of hospitalisations caused by 
HE over 6
  months (Hazard ratio 0.50; p=0.01). Thus the numbers needed to 
treat (NNT) = 9

*91% of patients in both groups were taking lactulose.

About Norgine

Norgine is a successful, independent European specialty
pharmaceutical company that has been established for over 100 years
and has a presence in all major European markets. In 2012, Norgine's
net product sales were cEUR250 million and the company employs over a
1,000 people.

Norgine's focus is the development and marketing of pharmaceutical
products that address significant unmet clinical needs in therapeutic
areas such as gastroenterology, hepatology, critical and supportive
care.

Norgine manufactures most of its own products in Hengoed, UK and
Dreux, France. For more information: http://www.norgine.com.

Product under licence from Alfa Wassermann S.p.A. XIFAXAN and
TARGAXAN are registered trademarks of the Alfa Wassermann group of
companies, licensed to the Norgine group of companies.

About Alfa Wassermann

Alfa Wassermann is a private pharmaceutical group with Head Quarters
in Bologna, Italy with its own Research, Development and
Manufacturing facilities. In 2012, Alfa Wassermann net sales were
above EUR360million and the company employs over 1300 people. It has
a growing number of affiliate companies in both Europe as well as in
emerging markets such as Russia, China and Mexico. Its main product
Rifaximin-alpha is a gut-selective antibiotic which has been
prescribed for 24 years, under the Trade Names of NORMIX(R),
XIFAXAN(R) and others, in 33 countries, including the USA where Salix
Pharmaceuticals is the exclusive licensee. Alfa Wassermann has also
developed other important products: Sulodexide (VESSEL(R)), a
heparinoid for thromboembolic diseases, and Parnaparin (FLUXUM(R)), a
low molecular weight heparin for the treatment and prophylaxis of
deep-vein thrombosis. For more information, please visit ALFA
WASSERMANN's web site at http://www.alfawassermann.it

ALFA WASSERMANN(R), the ALFA WASSERMANN logo, NORMIX(R) and
XIFAXAN(R) VESSEL FLUXUM are registered trademarks of Alfa Wassermann
group of companies.

References

i. Bass, N.M. et al. N Engl J Med, 2010: 362(12): 1071-81)

ORIGINAL APA-OTS TEXT - THE INFORMATION CONTAINED IN THIS PRESS RELEASE IS SUBJECT TO THE EXCLUSIVE RESPONSIBILITY OF THE ISSUER | PRN

print